Sign In
MUTATIONAL AND SUBGROUP ANALYSES OF LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS TREATED WITH LUSPATERCEPT: PHASE 2 PACE-MDS STUDY
Author(s): ,
Uwe Platzbecker
Affiliations:
Universitätsklinikum Carl Gustav Carus,Dresden,Germany
,
Aristoteles Giagounidis
Affiliations:
Marien Hospital Düsseldorf,Düsseldorf,Germany
,
Philipp Kiewe
Affiliations:
Onkologischer Schwerpunkt am Oskar-Helene-Heim,Berlin,Germany
,
Ulrich Germing
Affiliations:
Universitätsklinikum Düsseldorf,Düsseldorf,Germany
,
Katharina Götze
Affiliations:
Ill. Department of Medicine, Hematology and Medical Oncology, Technical University of Munich,Munich,Germany
,
Karin Mayer
Affiliations:
University Hospital Bonn,Bonn,Germany
,
Markus Radsak
Affiliations:
Johannes Gutenberg-Universität,Mainz,Germany
,
Thomas Wolff
Affiliations:
OncoResearch Lerchenfeld UG,Hamburg,Germany
,
Joerg Chromik
Affiliations:
Universitätsklinikum Frankfurt, Goethe Universität,Frankfurt/Main,Germany
,
Uta Oelschlägel
Affiliations:
Universitätsklinikum Carl Gustav Carus,Dresden,Germany
,
Joseph Reynolds
Affiliations:
Acceleron Pharma Inc,Cambridge,United States
,
Carolyn Barron
Affiliations:
Acceleron Pharma Inc,Cambridge,United States
,
Chris Rovaldi
Affiliations:
Acceleron Pharma Inc,Cambridge,United States
,
Rajasekhar NVS Suragani
Affiliations:
Acceleron Pharma Inc,Cambridge,United States
,
Xiaosha Zhang
Affiliations:
Acceleron Pharma Inc,Cambridge,United States
,
Abderrahmane Laadem
Affiliations:
Celgene,Summit,United States
,
Peter G Linde
Affiliations:
Acceleron Pharma Inc,Cambridge,United States
Matthew L Sherman
Affiliations:
Acceleron Pharma Inc,Cambridge,United States
EHA Library. Platzbecker U.
Jun 15, 2018; 214957
Prof. Dr. Uwe Platzbecker
Prof. Dr. Uwe Platzbecker
Contributions
×
Abstract

Abstract: PF498

Type: Poster Presentation

Presentation during EHA23: On Friday, June 15, 2018 from 17:30 - 19:00

Location: Poster area

Background
Serious hematologic conditions such as MDS are associated with an erythroid maturation defect leading to anemia and other clinical sequelae. Luspatercept (ACE-536) is being developed as an erythroid-maturation agent (EMA) for treatment of anemia in lower-risk MDS. Luspatercept binds to select TGF-β superfamily ligands reducing aberrant Smad2/3 signaling and promoting late-stage erythroid maturation and increased hemoglobin (Hgb) levels (Suragani R, Nat Med, 2014; Platzbecker U, Lancet Oncol, 2017).

Aims
This ongoing, phase 2, multicenter, open-label study followed by a long-term extension (ext) study evaluates the effects of luspatercept in pts with lower-risk MDS. Endpoints include long-term safety and tolerability, erythroid response (IWG HI-E), RBC transfusion independence (RBC-TI, ≥8 weeks), duration of HI-E, pharmacodynamic and iron metabolism biomarkers, and pt-reported quality of life (QoL). New analyses focus on mutational and bone marrow characteristics of luspatercept responders. 

Methods
Inclusion criteria: MDS IPSS low or int-1, age ≥18 yr, Hgb <10 g/dL (if <4U RBC/8 weeks), no prior HMA, and no current lenalidomide or erythropoiesis-stimulating agent (ESA). Pts are treated every 3 weeks subcutaneously for up to 5 doses (titration up to 1.75 mg/kg) in the base study (NCT01749514) and are then eligible for long-term treatment up to 5 additional years (NCT02268383). Baseline bone marrow and blood samples were analyzed by central morphology and flow cytometry according to ELN guidelines for evaluation of erythroid precursors and soluble transferrin receptor. 

Results
Data (as of 08Sept2017) were available for 88 pts treated at dose levels ≥0.75 mg/kg with evaluable mutational data at baseline. All 88 pts were evaluable for IWG HI-E. Increased response rates were seen in pts with EPO < 500 IU/L. Response rates were also increased in the SF3B1 mutated group vs the non-SF3B1 mutated group. Responders in both the SF3B1 mutated and non-SF3B1 mutated groups had lower M/E ratios at baseline than non-responders with a parallel increase in erythroid precursors. 

 

Conclusion
Increased response rates in patients with lower M/E ratios suggest that an expanded erythroid population at baseline may be associated with response to luspatercept, supporting the concept that luspatercept is acting as an erythroid-maturation agent (EMA). Patients with and without the SF3B1 mutation with EPO < 500 IU/L experienced substantial response rates, consistent with earlier results. Additional analyses are ongoing to understand the role of other biomarkers such as mutation status and how they may impact the biology and influence response. As there is not one distinct profile of responder characteristics, this may suggest the possibility that luspatercept may work in a broad range of genotypes and phenotypes. 

Session topic: 10. Myelodysplastic syndromes – Clinical

Keyword(s): Erythroid differentiation, Erythropoieisis, MDS, TGF-

Premium Sponsors
Major Sponsors

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies